Emergent Biosolutions Inc (EBS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $297.69M
Last updated: Nov 17, 2026 at 11:05 AM ET
Emergent Biosolutions Inc (EBS) Stock Forecast
Analysts expect Emergent Biosolutions (EBS) to earn $0.29 per share in the fiscal year ending Dec 31, 2026, on revenue of $646.79M. Of 3 analysts, 2 rate the stock Buy or Strong Buy, 0 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 3.00, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 2 | 66.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 33.3% |
- Consensus
- Hold
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 262.1% and revenue estimates rise 8.7%.
- Fiscal year ending Dec 31, 2026
- $0.29
- EPS consensus, revenue $646.79M
- Fiscal year ending Dec 31, 2027
- $1.05
- EPS consensus, revenue $703.33M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.29 | $0.22 to $0.36 | 2 | $646.79M | $635.40M to $659.96M | 3 |
| Dec 31, 2027 | $1.05 | $1.05 to $1.05 | 1 | $703.33M | $596.66M to $810.00M | 2 |
Quarterly Estimates
The EPS consensus falls from -$0.17 for the quarter ending Dec 31, 2026 to -$0.53 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.17 | -$0.22 to -$0.12 | 4 | $139.04M | $123.48M to $159.60M | 4 |
| Mar 31, 2027 | -$0.53 | -$0.53 to -$0.53 | 1 | $175.00M | $175.00M to $175.00M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 69.5% from $0.95.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.29 | $0.36 | $0.36 | $0.36 | $0.95 | -69.5% |
| Quarter ending Mar 31, 2027 | -$0.53 | -$0.53 | -$0.04 | -$0.04 | -$0.04 | N/A |
Frequently Asked Questions About EBS
What is the EBS stock forecast?
Consensus analyst estimates put Emergent Biosolutions's EPS at $0.29 for the fiscal year ending Dec 31, 2026, on revenue of $646.79M. The consensus rating from 3 analysts is Hold.
How do analysts rate EBS stock?
Of 3 analysts covering Emergent Biosolutions, 0 rate it Strong Buy, 2 Buy, 0 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from EBS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.29, with estimates from $0.22 to $0.36 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.05, with estimates from $1.05 to $1.05 from 1 analyst.
What revenue do analysts expect from Emergent Biosolutions next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $646.79M, with estimates from $635.40M to $659.96M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $703.33M, with estimates from $596.66M to $810.00M.
How many analysts cover EBS?
3 analysts rate Emergent Biosolutions stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
EBS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts